Combination treatment for advanced stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of drugs for advanced stomach cancer that has spread or come back. It aims to see if adding an immune therapy and a bacterial extract to standard chemotherapy can help control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery.
- You are between 18 and 75 years old.
- You have not had prior systemic treatment for this advanced cancer, though you may have had earlier treatment that finished at least 6 months ago.
- You are physically active and able to care for yourself (ECOG status 0 or 1).
- You have at least one measurable tumor that can be seen on scans.
- You have a tissue sample available for PD-L1 testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This trial tests a new drug called ASP2138 combined with chemotherapy and pembrolizumab for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. It may help if your tumor has certain markers (CLDN18.2 and PD-L1) and you haven't had prior chemotherapy for advanced disease.
This trial tests a new drug combined with chemotherapy before surgery for stomach cancer that has spread to nearby areas. It aims to shrink the tumor to make surgery more successful.
This trial tests a new combination of two drugs (QLS31905 and QL2107) plus standard chemotherapy for stomach cancer that has spread and tests positive for a specific marker (CLDN18.2). It's for people who haven't had treatment yet, and the goal is to see if it shrinks tumors better than standard care.
This trial tests new combinations of drugs alongside standard chemotherapy for people with advanced stomach or esophagus cancer that has not been treated yet. It aims to see if these combinations can shrink tumors or slow down the cancer better than current options.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.